|English: Doxepin Polski: Doxepin - Doksepina (Photo credit: Wikipedia)|
64% of patients chose to continue doxepin after study completion.
*Click here to see full article.
From Oncology Times:
|English: Doxepin Polski: Doxepin - Doksepina (Photo credit: Wikipedia)|
BiovaxID: An Interview with Dr. Eduardo M. Sotomayor (Part 4 of a series):
By Ross Bonander, November 09, 2012
"In this next installment in my ongoing series,"BiovaxID: On the Trail of the Lymphoma Vaccine", I interviewed one of the world's leading authorities on lymphoma, Dr. Eduardo M. Sotomayor.
Dr. Sotomayor serves as Chair of the Department of Malignant Hematology and holds the Susan and John Sykes Endowed Chair in Hematologic Malignancies at H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida."
Doctors are men who prescribe medicines of which they know little, to cure diseases of which they know less, in human beings of whom they know nothing. (1760)
“Take a moment to imagine what it would be like to live robustly to the ripe old age of 100 or more. You wouldn’t die of any particular illness, and you wouldn’t gradually waste away under the spell of some awful, enfeebling disease that began years or decades earlier.It may sound far-fetched, but it is possible to live a long, disease-free life. Most of the conditions that kill us, including cancer and heart disease, could be prevented or delayed by a new way of looking at and treating health. The end of illness is near.Today, we mostly wait for the body to break before we treat it. When I picture what it will be like for my two children to stay in good health as independent adults in 10 or 20 years, I see a big shift from our current model.”
“Any man who is intelligent must, on considering that health is of the utmost value to human beings, have the personal understanding necessary to help himself in diseases, and be able to understand and to judge what physicians say and what they administer to his body, being versed in each of these matters to a degree reasonable for a layman.”
Cancer touches the lives of all Albertans – 1 in 2 men will develop cancer in their lifetimes and 1 in 3 women will receive a cancer diagnosis.
One in four Albertans will die of cancer. (1)
The Tomorrow Project is the largest health research project undertaken in Alberta. Its goal is to find out more about the causes of cancer and other health conditions so researchers will be able to develop better strategies to improve our health in the future.
The Tomorrow Project is looking for 50,000 volunteers aged 35 to 69 who have never had cancer to participate. Once enrolled, participants are asked to fill out a survey about their health and lifestyle, and go to a study centre located in Calgary or Edmonton where they will be measured by trained staff, and asked to donate a sample of urine and blood or saliva. Those who can’t get to a study centre can request a mail-in saliva collection kit to use and send back.
To enroll today, simply call toll-free 1 877 919 9292 or visit www.in4tomorrow.ca. Tell as many friends, family, neighbours and colleagues about this important province-wide health initiative, and encourage them to join. The commitment made today will help create a cancer-free tomorrow.
The Tomorrow Project is supported by the Alberta Cancer Foundation, the Alberta Cancer Prevention Legacy Fund (administered by Alberta Innovates-Health Solutions), the Canadian Partnership Against Cancer, and Alberta Health Services.
1. Cancer Surveillance: 2008 Report on Cancer Statistics in Alberta. Edmonton: Surveillance and Health Status Assessment, Alberta Health Services, 2010.
If Hockey Won't Fight Cancer, Hockey Fans Will : The Hockey Writers:
A great cause intiated by my colleague at The Hockey Writers, Ross Bonander who is also a healthcare journalist.
"The other day I wrote “Who Fights Cancer in a Lockout?” at Overtime, noting that should the lockout cancel games in October, it also cancels the biggest charity initiative of the NHL season, “Hockey Fights Cancer” (HFC). This means that the league, the players, and the fans won’t take part in the league-wide initiative, resulting in about $1 million not going to cancer charities this year.
Well if the NHL won’t do it, and the NHLPA can’t do it, then we the fans should.
To that end, I’ve created a grassroots fundraising team with the Livestrong Foundation entitled “Hockey Fans Fight Cancer.”
100 % of donations go to Livestrong.
Two Hundred Years of Cancer Research — NEJM
Excellent article from NEJM; the full article available at above link.
More Breast Cancer Treatments Hinted in Study - NYTimes.com: "In findings that are fundamentally reshaping the scientific understanding of breast cancer, researchers have identified four genetically distinct types of the cancer. And within those types, they found hallmark genetic changes that are driving many cancers.
These discoveries, published online on Sunday in the journal Nature, are expected to lead to new treatments with drugs already approved for cancers in other parts of the body and new ideas for more precise treatments aimed at genetic aberrations that now have no known treatment.
The study is the first comprehensive genetic analysis of breast cancer, which kills more than 35,000 women a year in the United States. The new paper, and several smaller recent studies, are electrifying the field.
“This is the road map for how we might cure breast cancer in the future,” said Dr. Matthew Ellis of Washington University, a researcher for the study."
|English: Mario Lemieux at the HSBC Arena in Buffalo. (Photo credit: Wikipedia)|
Pain Management - Oncology News Article | Onabotulinumtoxina for treatment of focal cancer pain after surgery and/or radiation |4134185
Pain Medicine, 07/17/2012 Clinical Article
Mittal S et al. – Local treatment with onabotulinumtoxinA can significantly reduce pain and improve quality of life in cancer patients suffering from pain in the area of surgery and radiation and was well tolerated in cancer patients.
Authors studied the effect of onabotulinumtoxinA in seven cancer patients who suffered from severe focal pain (visual analog scale >5) at the site of local surgery or radiotherapy or both.
OnabotulinumtoxinA (20–100 units) was injected into the focal pain areas (skin or muscle or both).
Five of seven patients were followed beyond 1 year (1.5–5 years) with repeat treatment.
All seven patients reported a significant improvement in pain (mean drop in visual analog scale score of 5.1).
They described their response on the patient global assessment as satisfactory (two patients) or very satisfactory (five patients).
Six of seven patients found the pain relief associated with significant improvement in quality of life.
One patient developed weakness of jaw muscles after bilateral masseter injection that was not observed during second injection (reduced dose).
Improvements with treatment persisted with repeat injections during long–term follow–up (five patients). "
|TEDatNewYork_0726_IMG_2149_1920 (Photo credit: TED Conference)|
|Leo Tolstoy 1848 (Photo credit: Wikipedia)|
Pain Medicine News - Is It Time To Change the Way We Report Pain?
"A study by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) found that, in addition to the importance of assessing pain relief and improvement in physical and emotional functioning, a comprehensive outcome measure must also consider changes in “fatigue, sleep, home and family care, social and recreational activities, interpersonal relationships, and sexual activities.”13 In 2005, IMMPACT recommended several core outcome measures to be used in clinical trials14; however, few of these measures were designed specifically to evaluate the efficacy of pain management treatments, or were normed on a pain population (e.g., Beck Depression Inventory, Profile of Mood States, etc.). Casarett et al15 found that in addition to the reduction of pain, patients commonly cited improvement in sleep and increased ability to function as meaningful clinical end points. Moreover, Robinson et al16 found patients considered decreased fatigue, distress and interference as indicators of treatment success.
In response to these concerns, the global pain scale (GPS) was created. The GPS was designed to capture the multidimensionality of pain but also to provide a single score that could be used to track changes (e.g., as the result of a clinical intervention).17 Rooted in the biopsychosocial model, the GPS assesses physical pain, affective effects of pain, specific clinical outcomes, and the degree to which the pain interferes with ADLs.
We believe the GPS can be used as a standardized measure of treatment efficacy. It uniquely tracks clinical outcomes after a pain-relieving treatment has been initiated. The GPS can be administered to the patient in the waiting room and scored by the support staff, thus resulting in a robust assessment of pain in one numerical score that the physician can employ to formulate treatment plans. For research, the GPS can be used to measure pain scores and to follow pain treatment efficacy. The GPS is available free for physicians’ use in their practices or research studies, at http://www.paindoctor.com/global-pain-scale .
"Health Canada is informing Canadians that it is assessing the possibility of an increased risk of cancer with long-term use of the drug calcitonin. Patients who are taking a calcitonin medicine who have questions should speak to their health care professional before they consider stopping their calcitonin treatment."
"July 20, 2012 — The European equivalent of the US Food and Drug Administration (FDA) yesterday recommended withdrawing calcitonin nasal spray — indicated for treating osteoporosis in the European Union — because of an increased risk for cancer.
The European Medicines Agency (EMA) also said that the long-term use of calcitonin-containing medicines delivered by injection or infusion increases the risk for cancer. As a consequence, the EMA recommended that these drugs be used only on a short-term basis for 3 conditions for which they had previously been approved in the European Union: Paget's disease, acute bone loss resulting from sudden immobilization, and hypercalcemia caused by cancer.
Calcitonin in any formulation should not be used to treat osteoporosis at all, the agency said.
In the United States, 2 nasal-spray versions of calcitonin are FDA-approved for treating postmenopausal osteoporosis in women: Fortical (Upsher-Smith Laboratories) and Miacalcin (Novartis). Neither of the labels for the 2 drugs contains restrictions on how they should be used or a warning about the risk for cancer.
Calcitonin, also called calcitonin-salmon, is a synthetic copy of a polypeptide hormone secreted by the ultimobranchial gland of salmon."
Read more: http://www.medscape.com/viewarticle/767814
|Thomas Hicks running the marathon at the 1904 Summer Olympics (Photo credit: Wikipedia)|
"Performance-enhancing drugs have cast a long shadow on the modern Olympics. Whether the agents are the strychnine, heroin, cocaine, and morphine that athletes used in Athens in 1896 or the amphetamines, steroids, and erythropoietin that some use today, the dilemma remains the same. As a sports medicine specialist noted in 2004, the “attraction of performance-enhancing drugs is simply that they permit the fulfillment of the mythical promise of boundless athletic performance — the hubristic `faster, higher, stronger' motto of the Olympic Games” (2004). The ensuing systems of medical surveillance have led, inevitably, to “a new type of competition,” in which some athletes try to stay one step ahead of the authorities (2001).
The following is just a sampling of some fantastic programs available to cancer patients in Alberta:
"At Wellspring, people living with cancer tell us what helps them the most – having access to information, receiving support, and learning new ways to cope. Wellspring Calgary exists to inform, support, and empower patients, families and caregivers by helping them to address the fear, isolation, disruption and practical problems which cancer can bring to our lives. All of our programs, services and resources are offered free of charge and without referral."
Sampling of programs offered free of charge: